Navidea Biopharmaceuticals, Inc (NAVB) Financials

NAVB Assets vs Liabilities

DateAssetsLiabilities
2023-09-30 5.7 million 8.7 million
2023-06-30 8.2 million 9.0 million
2023-03-31 2.4 million 11.9 million
2022-12-31 4.4 million 12.5 million

NAVB Free Cash Flow and Stock based compensation

Graph available only for supporters. Become a supporter to see it.
DateFree Cash FlowStock based compensation
2023-09-30 -10.3 million 10347
2023-06-30 4.6 million -33842
2023-03-31 -1.8 million 19669
2022-12-31 -2.5 million 34895

NAVB Net Income

No data available :(

NAVB Cash and Debt

Graph available only for supporters. Become a supporter to see it.
DateCashDebtCapital Lease
2023-09-30 3.9 million - 10696
2023-06-30 6.1 million - 19564
2023-03-31 33795 - 11298
2022-12-31 2.0 million - 20288

NAVB Shares Outstanding

Graph available only for supporters. Become a supporter to see it.
DateShares Outstanding
2023-09-30 99.4 million
2023-06-30 48.2 million
2023-03-31 32.7 million
2022-12-31 32.4 million

NAVB Expenses

Graph available only for supporters. Become a supporter to see it.
DateCapexR&DG&AS&M
2023-09-30 16523 829613 1.3 million -
2023-06-30 65337 1.1 million 1.3 million -
2023-03-31 39409 1.3 million 1.2 million -
2022-12-31 72039 1.9 million 1.3 million -

NAVB Cost of Revenue

Graph available only for supporters. Become a supporter to see it.
DateRevenueCost of Revenue
2023-09-30 - -
2023-06-30 - -
2023-03-31 - -
2022-12-31 610 50036

NAVB

Price: $0.04

52 week price:
0.02
0.31

Earnings Per Share: -0.20 USD

P/E Ratio: -0.17

Exchange: PNK

Sector: Healthcare

Industry: Biotechnology

Volume: 89200

Market Capitalization: 4.0 million

Links: